GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adicet Bio Inc (FRA:1IJA) » Definitions » ROE % Adjusted to Book Value

Adicet Bio (FRA:1IJA) ROE % Adjusted to Book Value : -70.70% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Adicet Bio ROE % Adjusted to Book Value?

Adicet Bio's ROE % for the quarter that ended in Mar. 2024 was -52.32%. Adicet Bio's PB Ratio for the quarter that ended in Mar. 2024 was 0.74. Adicet Bio's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was -70.70%.


Adicet Bio ROE % Adjusted to Book Value Historical Data

The historical data trend for Adicet Bio's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adicet Bio ROE % Adjusted to Book Value Chart

Adicet Bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial - -69.89 -14.86 -19.68 -144.19

Adicet Bio Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -47.80 -118.56 -299.26 -152.19 -70.70

Competitive Comparison of Adicet Bio's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Adicet Bio's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adicet Bio's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adicet Bio's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Adicet Bio's ROE % Adjusted to Book Value falls into.



Adicet Bio ROE % Adjusted to Book Value Calculation

Adicet Bio's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-60.56% / 0.42
=-144.19%

Adicet Bio's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-52.32% / 0.74
=-70.70%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adicet Bio ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Adicet Bio's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Adicet Bio (FRA:1IJA) Business Description

Industry
Traded in Other Exchanges
Address
200 Clarendon Street, Floor 6, Boston, MA, USA, 02116
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. The company operates and manages its business as one reportable and operating segment, which is the business of research and development of allogeneic immunotherapies for cancer and other diseases.

Adicet Bio (FRA:1IJA) Headlines

No Headlines